SEOUL, October 29 (AJP) - The board of the Hilleman Institute, a leading global vaccine research organization, visited SK Bioscience’s headquarters on Tuesday to explore deeper cooperation in vaccine development and manufacturing, the company said Wednesday.
The visit marked a significant step in strengthening strategic ties between the two organizations. It was the first time the Hilleman Institute’s board — established by pharmaceutical giant MSD and the U.K.-based nonprofit Wellcome Trust — held a meeting in South Korea. The institute, based in Singapore, focuses on improving vaccine access and public health in low- and middle-income countries.
During the visit, board members toured SK Bioscience’s research and production facilities, evaluating the company’s R&D infrastructure, manufacturing systems, and global commercialization capabilities.
According to SK Bioscience, the delegation recognized the company’s potential as a collaborative hub for global vaccine research and production.
Executives from both sides also held in-depth discussions on expanding joint research and technology exchange, building on their existing partnership.
SK Bioscience and the Hilleman Institute signed a strategic collaboration agreement in 2023 to jointly develop a next-generation Zaire Ebola vaccine. Since then, the partnership has expanded to include process development, technology transfer, and vaccine candidate commercialization.
“Hosting the Hilleman Institute’s board in Korea underscores the depth of our partnership,” said Ahn Jae-yong, president of SK Bioscience. “We look forward to expanding collaboration to strengthen the global vaccine supply chain and improve preparedness for infectious disease threats.”
SK Bioscience aims to position itself as a central player in global vaccine research, leveraging partnerships with international health institutions to broaden access to next-generation immunization technologies.
* This article, published by Aju Business Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.
